Mabpharm (HKSE:02181) Interest Expense : HK$-10.48 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Mabpharm's interest expense for the six months ended in Dec. 2023 was HK$ -5.56 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-10.48 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Mabpharm's Operating Income for the six months ended in Dec. 2023 was HK$ -115.95 Mil. Mabpharm's Interest Expense for the six months ended in Dec. 2023 was HK$ -5.56 Mil. Mabpharm did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mabpharm Interest Expense Historical Data

The historical data trend for Mabpharm's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Interest Expense Chart

Mabpharm Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-8.56

-4.67

-2.94

-8.03

-10.48

Mabpharm Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial								-1.39	-3.64	-4.56	-4.92	-5.56

Mabpharm Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-10.48 Mil.

Mabpharm (HKSE:02181) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mabpharm's Interest Expense for the six months ended in Dec. 2023 was HK$-5.56 Mil. Its Operating Income for the six months ended in Dec. 2023 was HK$-115.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was HK$147.46 Mil.

Mabpharm's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Mabpharm did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Mabpharm (HKSE:02181) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300

Website

http://www.mabpharm.cn

Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).

Executives

Guo Jianjun	2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines